Clinical Trial Update: A Study to Evaluate Nivolumab in Patients With Unresectable Advanced/Metastatic Gastric Cancer and Gastroesophageal Junction Cancer

View source ↗

Summary

A completed clinical trial evaluating nivolumab in patients with unresectable, advanced or metastatic gastric cancer and gastroesophageal junction cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• OPDIVO (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Gastric Cancer, Gastroesophageal Junction Cancer | Status: COMPLETED